Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor.
Itraconazole, a new orally active triazole antifungal, has been tested in patients with pityriasis versicolor. A comparison of different dose schedules was carried out in 73 patients. A regime of 100 mg itraconazole daily for 15 days gave a 100% response rate; 200 mg daily for 5 days gave an 80% response rate. Two patients, who had received 50 mg itraconazole for 14 days, relapsed within 2 months of finishing treatment. Only two patients reported minor side-effects.
D000284:Administration, Oral; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D014010:Tinea Versicolor / Q000188:drug therapy*
D017964:Itraconazole; D007654:Ketoconazole